User login
Key clinical point: Patients with atopic dermatitis (AD) who received dupilumab therapy experienced rapid and sustained disease control for up to 12 months after therapy initiation.
Major finding: The mean AD Control Tool score reduced from 15.8 at baseline to 6.4 and 4.4 at months 1 and 12, respectively (both P < .001). Furthermore, at month 1, with the use of concomitant AD therapies, flares and skin symptoms, such as skin pain/soreness, hot/burning feeling, and sensitivity to touch, were reduced and health-related quality of life improved with effects sustained until month 12 (all P < .001).
Study details: Findings are from a prospective, longitudinal RELIEVE-AD study including 699 patients with moderate-to-severe AD who initiated treatment with dupilumab and were followed up for 12 months.
Disclosures: The study was funded by Sanofi and Regeneron Pharmaceuticals. The authors declared serving as consultants, advisory board members, and speakers or receiving honoraria and funding from several sources. Some of the authors reported being employees or shareholders of Sanofi, Regeneron Pharmaceuticals, and others.
Source: Strober B et al. JAMA Dermatol. 2021 (Dec 15). Doi: 10.1001/jamadermatol.2021.4778.
Key clinical point: Patients with atopic dermatitis (AD) who received dupilumab therapy experienced rapid and sustained disease control for up to 12 months after therapy initiation.
Major finding: The mean AD Control Tool score reduced from 15.8 at baseline to 6.4 and 4.4 at months 1 and 12, respectively (both P < .001). Furthermore, at month 1, with the use of concomitant AD therapies, flares and skin symptoms, such as skin pain/soreness, hot/burning feeling, and sensitivity to touch, were reduced and health-related quality of life improved with effects sustained until month 12 (all P < .001).
Study details: Findings are from a prospective, longitudinal RELIEVE-AD study including 699 patients with moderate-to-severe AD who initiated treatment with dupilumab and were followed up for 12 months.
Disclosures: The study was funded by Sanofi and Regeneron Pharmaceuticals. The authors declared serving as consultants, advisory board members, and speakers or receiving honoraria and funding from several sources. Some of the authors reported being employees or shareholders of Sanofi, Regeneron Pharmaceuticals, and others.
Source: Strober B et al. JAMA Dermatol. 2021 (Dec 15). Doi: 10.1001/jamadermatol.2021.4778.
Key clinical point: Patients with atopic dermatitis (AD) who received dupilumab therapy experienced rapid and sustained disease control for up to 12 months after therapy initiation.
Major finding: The mean AD Control Tool score reduced from 15.8 at baseline to 6.4 and 4.4 at months 1 and 12, respectively (both P < .001). Furthermore, at month 1, with the use of concomitant AD therapies, flares and skin symptoms, such as skin pain/soreness, hot/burning feeling, and sensitivity to touch, were reduced and health-related quality of life improved with effects sustained until month 12 (all P < .001).
Study details: Findings are from a prospective, longitudinal RELIEVE-AD study including 699 patients with moderate-to-severe AD who initiated treatment with dupilumab and were followed up for 12 months.
Disclosures: The study was funded by Sanofi and Regeneron Pharmaceuticals. The authors declared serving as consultants, advisory board members, and speakers or receiving honoraria and funding from several sources. Some of the authors reported being employees or shareholders of Sanofi, Regeneron Pharmaceuticals, and others.
Source: Strober B et al. JAMA Dermatol. 2021 (Dec 15). Doi: 10.1001/jamadermatol.2021.4778.